MedTrace Logo

Concentration of Ertapenem in Colorectal Tissue

NCT00535652 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-02-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the tissue kinetics of ertapenem in colonic tissue from three hours up to six hours (25% of dosing interval) after administration of ertapenem.

Conditions

  • Diverticulosis, Colonic
  • Rectal Neoplasms
  • Colonic Neoplasms

Interventions

DRUG

Ertapenem

powder for infusion, 1 gram I.V., single dose over 30 min.

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Doris Henne-Bruns, Prof. Dr. · University of Ulm, Dept. of Visceral Surgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00535652 on ClinicalTrials.gov